Stay updated on Fruquintinib & Tislelizumab in Solid Tumors Clinical Trial
Sign up to get notified when there's something new on the Fruquintinib & Tislelizumab in Solid Tumors Clinical Trial page.

Latest updates to the Fruquintinib & Tislelizumab in Solid Tumors Clinical Trial page
- Check2 days agoChange DetectedThe page revision/version indicator was updated from v3.5.2 to v3.5.3.SummaryDifference0.0%

- Check9 days agoChange DetectedRevision: v3.5.2 has been added and Revision: v3.5.0 has been removed.SummaryDifference0.0%

- Check16 days agoNo Change Detected
- Check38 days agoChange DetectedRevision history updated: added Revision: v3.5.0 and removed Revision: v3.4.3.SummaryDifference0.0%

- Check45 days agoChange DetectedRevision updated from v3.4.2 to v3.4.3. No study content or essential features appear affected.SummaryDifference0.0%

- Check74 days agoChange DetectedThe page indicates a site-wide revision update to v3.4.2 and removal of the prior government-funding notice; these changes are maintenance-related and do not alter any trial details. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.4%

- Check81 days agoChange DetectedA site-wide notice about government funding lapse and NIH operating status was added, and the page revision updated from v3.4.0 to v3.4.1. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.4%

Stay in the know with updates to Fruquintinib & Tislelizumab in Solid Tumors Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Fruquintinib & Tislelizumab in Solid Tumors Clinical Trial page.